Discuss the role of backward integration in making pharmaceutical supply chains resilient.

Backward integration means moving upstream from finished formulations into the Key Starting Materials (KSMs), Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) that feed them. India supplies generics worldwide, yet roughly two-thirds of its bulk drug imports come from China [3] — making integration a strategic necessity, not merely an industrial choice.

How it builds resilience

• Breaks single-source dependence: concentration of KSM supply in one geography exposes India to export curbs and price spikes; domestic capacity converts that exposure into an option to produce [3].
• Restores lost upstream capacity: under the PLI scheme, Penicillin G manufacturing was revived at Kakinada SEZ after about three decades, alongside India's first fermentation-based potassium clavulanate plant at Nalagarh [1].
• Deepens value addition and jobs: the Penicillin G unit reports over 90% domestic value addition and the Atorvastatin unit over 80% [1].
• Protects health security downstream: Penicillin G yields 6-APA, the base for amoxicillin and ampicillin [1] — a break here cascades through primary-care antibiotic supply.
• Policy vehicle: PLI for Bulk Drugs — ₹6,940 crore, 41 critical products, greenfield only, 2020-21 to 2029-30, with 48 projects approved [2].

Why integration alone is insufficient

• Cost gap: imported APIs remain about 35-40% cheaper, so imports continue for economic reasons [3]. Capacity created is not capacity used.
• Time-bound support, permanent disadvantage: incentives lapse, but power and effluent costs of fermentation routes persist.
• Execution lag: several approved projects are yet to be commissioned [2].

Way forward

• Complete the Bulk Drug Parks [5] with shared effluent treatment, assured power and common utilities under an SPV, as the Katoch Committee recommended [4] — infrastructure lowers unit cost permanently, unlike incentives.
• Use public procurement preference for high domestic value addition to assure offtake.

Backward integration converts a trading relationship into productive capability, insuring an essential-medicines chain against disruption. Paired with park infrastructure and assured demand, it can make self-reliance in bulk drugs durable rather than incentive-dependent — advancing both Atmanirbhar Bharat and SDG-3's promise of access to essential medicines.